Senior Director, Medical Affairs
AbbottFull Time
Expert & Leadership (9+ years)
Candidates must possess over 10 years of experience in clinical research and strategy, with at least 8 years specifically in cardiovascular medicine within the pharmaceutical or medical device industry. A deep understanding of cardiovascular medicine, health technologies, clinical trial strategy, and digital health is essential. The role requires exceptional organizational and presentation skills, excellent attention to detail, and comfort in a fast-paced startup environment. A strategic mindset, patient-centric values, high ethical and compliance standards, and the ability to work independently with minimal supervision are also necessary. The position requires the ability to travel up to 25% and cultural intelligence for international settings.
The Director, Clinical Strategy will develop clinical evidence strategies for current and future products, ensuring alignment with product development and go-to-market plans. They will collaborate with Clinical Leadership to design clinical trials and real-world evidence studies that validate the safety, efficacy, and impact of Heartflow's AI-enabled products. This role involves supporting key scientific publication activities, representing the company to expert groups, medical societies, patient representatives, and regulatory bodies, and presenting at national and international scientific meetings. Responsibilities also include leading compliant scientific and medical exchange, establishing strong relationships with external advisors, and partnering with Medical Affairs and Clinical Leadership to plan and conduct Advisory Boards related to clinical trial strategy. The Director will monitor trends in cardiology, clinical AI, digital health, regulatory, and reimbursement landscapes to inform clinical strategy and collaborate with clinical advisors, key opinion leaders, investigators, and academic institutions.
Non-invasive cardiac testing for heart disease
HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to diagnose and treat heart disease more effectively without the need for invasive procedures, which reduces risks for patients and costs for healthcare providers. HeartFlow's main clients are healthcare professionals seeking safer diagnostic methods. The company offers several analyses, including FFRCT Analysis and Plaque Analysis, all of which have received FDA clearance and are available in multiple countries, including the United States, the United Kingdom, Japan, and Canada. Unlike many competitors, HeartFlow focuses on providing a comprehensive suite of analyses that enhance treatment planning. The goal of HeartFlow is to improve cardiovascular care by making it safer and more efficient for both patients and healthcare providers.